Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist

Circulation. 2018 Mar 20;137(12):1218-1220. doi: 10.1161/CIRCULATIONAHA.117.030117.

Authors

M Angelyn Bethel¹, John J V McMurray²

Affiliations

¹ Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom (M.A.B.) angelyn.bethel@dtu.ox.ac.uk.
² British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).

PMID: 29555706
DOI: 10.1161/CIRCULATIONAHA.117.030117

No abstract available

Keywords: SGLT-2 inhibitor; canagliflozin; cardiovascular diseases; diabetes mellitus; empagliflozin; mortality; myocardial infarction.

MeSH terms

Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / mortality
Cardiovascular Diseases / prevention & control*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / mortality
Humans
Risk Factors
Sodium-Glucose Transporter 2 / metabolism*
Sodium-Glucose Transporter 2 Inhibitors / adverse effects
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Time Factors
Treatment Outcome

Substances

SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors